LCAHA

LCAHA (LCA hydroxyamide) is a deubiquitinase USP2a inhibitor with IC50s of 9.7 μM and 3.7μM in Ub-AMC Assay and Di-Ub Assay, respectively. LCAHA destabilizes Cyclin D1 and induces G0/G1 arrest by inhibiting deubiquitinase USP2a[1].

Research Areas >> Cancer

Signaling Pathways >> Cell Cycle/DNA Damage >> Deubiquitinase

LCAHA inhibits HCT116wt and HCT116 p53-/- colon cancer cells viability with GI50s of 0.87±0.09 and 0.96±0.29μM, respectively, and the LD50s of 27.8±3.9 and 26.5±0.1μM, respectively[1]. Cell Viability Assay[1] Cell Line: HCT116wt and HCT116 p53-/- colon cancer cells Concentration: 0.01, 0.1, 1, 10, and 100 μM Incubation Time: 6 days Result: The GI50s are 0.87±0.09 and 0.96±0.29 μM for HCT116wt and HCT116 p53-/- colon cancer cells, respectively.

[1]. Katarzyna Magiera, et al. Lithocholic Acid Hydroxyamide Destabilizes Cyclin D1 and Induces G ₀/G₁ Arrest by Inhibiting Deubiquitinase USP2a. Cell Chem Biol. 2017 Apr 20;24(4):458-470.e18.